ATE494302T1 - Inhibitoren des extrazellulären hsp90 - Google Patents

Inhibitoren des extrazellulären hsp90

Info

Publication number
ATE494302T1
ATE494302T1 AT04718644T AT04718644T ATE494302T1 AT E494302 T1 ATE494302 T1 AT E494302T1 AT 04718644 T AT04718644 T AT 04718644T AT 04718644 T AT04718644 T AT 04718644T AT E494302 T1 ATE494302 T1 AT E494302T1
Authority
AT
Austria
Prior art keywords
extracellular hsp90
inhibitors
extracellular
hsp90
invasiveness
Prior art date
Application number
AT04718644T
Other languages
English (en)
Inventor
Daniel G Jay
Brenda K Eustace
Takashi Sakurai
Original Assignee
Univ Tufts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tufts filed Critical Univ Tufts
Application granted granted Critical
Publication of ATE494302T1 publication Critical patent/ATE494302T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
AT04718644T 2003-03-12 2004-03-09 Inhibitoren des extrazellulären hsp90 ATE494302T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45481303P 2003-03-12 2003-03-12
EP03015115A EP1457499A1 (de) 2003-03-12 2003-07-03 Inhibitoren des extrazellulären Hitzeschockproteins Hsp90
PCT/EP2004/002422 WO2004081037A1 (en) 2003-03-12 2004-03-09 Inhibitors of extracellular hsp90

Publications (1)

Publication Number Publication Date
ATE494302T1 true ATE494302T1 (de) 2011-01-15

Family

ID=32772103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04718644T ATE494302T1 (de) 2003-03-12 2004-03-09 Inhibitoren des extrazellulären hsp90

Country Status (13)

Country Link
EP (2) EP1457499A1 (de)
JP (1) JP4971788B2 (de)
CN (1) CN1860132A (de)
AT (1) ATE494302T1 (de)
CA (1) CA2518944C (de)
CY (1) CY1111365T1 (de)
DE (1) DE602004030890D1 (de)
DK (1) DK1603941T3 (de)
ES (1) ES2359240T3 (de)
PL (1) PL1603941T3 (de)
PT (1) PT1603941E (de)
SI (1) SI1603941T1 (de)
WO (1) WO2004081037A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7959915B2 (en) * 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
WO2006050501A2 (en) * 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
EP1817295B1 (de) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Hsp90-aktivität modulierende triazolverbindungen
JP5118039B2 (ja) 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
JP2010515020A (ja) * 2006-12-21 2010-05-06 ノバルティス アーゲー 抗体定量法
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
SG187502A1 (en) 2008-02-01 2013-02-28 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
WO2010001989A1 (ja) * 2008-07-03 2010-01-07 協和発酵キリン株式会社 癌幹細胞及び／または癌前駆細胞の減少剤並びに癌の再発及び／または転移の予防剤
SG10201601279SA (en) * 2008-08-18 2016-03-30 Mesoblast Inc Monoclonal Antibody STRO-4
CN101942017B (zh) 2009-07-07 2013-08-14 清华大学 一种新的肿瘤标志物
CN103694332B (zh) * 2009-07-07 2017-07-11 清华大学 一种新的肿瘤标志物
EP2560640A1 (de) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer
EA201490230A1 (ru) 2011-07-08 2014-06-30 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Применение меченых ингибиторов hsp90
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
CN105652011B (zh) * 2014-11-20 2017-09-22 深圳市安群生物工程有限公司 检测人HSP90α‑2蛋白的荧光免疫层析试纸及其制备方法
CN111197057B (zh) * 2018-11-19 2024-04-19 中国科学院分子细胞科学卓越创新中心 调控免疫细胞迁移的组合物和方法
US20220010008A1 (en) * 2018-12-12 2022-01-13 Shanghai Pharmaexplorer Co., Ltd. Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
CN109568311A (zh) * 2018-12-13 2019-04-05 中国人民解放军总医院 坦螺旋霉素在制备抗菌消炎药物中的应用
CN110511277B (zh) * 2019-09-11 2022-07-26 江苏莱森生物科技研究院有限公司 一种抗hsp90单克隆抗体及其应用
CN115109757B (zh) * 2022-05-11 2023-06-02 江南大学 一株分泌新生霉素单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
EP1161231A2 (de) * 1999-03-12 2001-12-12 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Verfahren zur hemmung eines chaperonproteins
GB0008305D0 (en) * 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections

Also Published As

Publication number Publication date
DK1603941T3 (da) 2011-04-26
JP2007524586A (ja) 2007-08-30
CY1111365T1 (el) 2015-08-05
PT1603941E (pt) 2011-03-31
PL1603941T3 (pl) 2011-06-30
EP1457499A1 (de) 2004-09-15
DE602004030890D1 (de) 2011-02-17
JP4971788B2 (ja) 2012-07-11
CN1860132A (zh) 2006-11-08
CA2518944A1 (en) 2004-09-23
WO2004081037A1 (en) 2004-09-23
EP1603941B1 (de) 2011-01-05
CA2518944C (en) 2013-07-30
SI1603941T1 (sl) 2011-05-31
ES2359240T3 (es) 2011-05-19
EP1603941A1 (de) 2005-12-14

Similar Documents

Publication Publication Date Title
CY1111365T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΕΞΩΚΥΤΤΑΡΙΚΗΣ Hsp90
ATE408601T1 (de) Fredericamycin-derivate
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
WO2003080582A3 (de) Fredericamycin-derivate
GB0223040D0 (en) Therapeutic compounds
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
DE60313624D1 (de) Derivate von heteroarylnitrilverbindungen
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2004078756A3 (en) Jnk inhibitors
WO2004101565A3 (en) Jnk inhibitors
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
WO2006088483A3 (en) Compositions and methods for inhibiting the synthesis or expression of mmp-1
AU2003242512A8 (en) Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease
WO2005023191A3 (en) Rage-related methods and compositions for treating glomerular injury
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
NO20050640L (no) Rutenium anticancer komplekser
ATE314043T1 (de) Derivate von aza-spiroverbindungen zur behandlung von schmerzen
TW200503672A (en) 2-aminobenzoyl derivatives
WO2005016958A3 (en) Compounds for treating tumors
DE502004003212D1 (de) Verbindungen, die faktor viia inhibieren
ATE412411T1 (de) Pmcol zur behandlung von prostatakrebs
BRPI0407681A (pt) sulfamatos de d-homoestra-1,3,5(10)-trien-3-ila 2-substituìdos ativos antitumorais
GB0015446D0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivates,taxanes and/or antimetabolites
NO20055650L (no) Ruteinum (II)-komplekser for behandling av tumorer
AU2003212990A8 (en) Novel compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1603941

Country of ref document: EP